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in the Asia–Pacific region
Rintis Noviyanti1, Olivo Miotto2,3,4, Alyssa Barry5,6,7,8, Jutta Marfurt9, Sasha Siegel3,9, Nguyen Thuy‑Nhien10,
Huynh Hong Quang11, Nancy Dian Anggraeni12, Ferdinand Laihad13, Yaobao Liu14, Maria Endang Sumiwi13,
Hidayat Trimarsanto1, Farah Coutrier1, Nadia Fadila1, Najia Ghanchi15, Fatema Tuj Johora16,
Agatha Mia Puspitasari1, Livingstone Tavul17, Leily Trianty1, Retno Ayu Setya Utami1, Duoquan Wang18,
Kesang Wangchuck19, Ric N. Price9,2,20 and Sarah Auburn9,2,20*

Abstract
The Asia–Pacific region faces formidable challenges in achieving malaria elimination by the proposed target in 2030.
Molecular surveillance of Plasmodium parasites can provide important information on malaria transmission and adap‑
tation, which can inform national malaria control programmes (NMCPs) in decision-making processes. In November
2019 a parasite genotyping workshop was held in Jakarta, Indonesia, to review molecular approaches for parasite
surveillance and explore ways in which these tools can be integrated into public health systems and inform policy.
The meeting was attended by 70 participants from 8 malaria-endemic countries and partners of the Asia Pacific
Malaria Elimination Network. The participants acknowledged the utility of multiple use cases for parasite genotyping
including: quantifying the prevalence of drug resistant parasites, predicting risks of treatment failure, identifying major
routes and reservoirs of infection, monitoring imported malaria and its contribution to local transmission, character‑
izing the origins and dynamics of malaria outbreaks, and estimating the frequency of Plasmodium vivax relapses.
However, the priority of each use case varies with different endemic settings. Although a one-size-fits-all approach
to molecular surveillance is unlikely to be applicable across the Asia–Pacific region, consensus on the spectrum of
added-value activities will help support data sharing across national boundaries. Knowledge exchange is needed
to establish local expertise in different laboratory-based methodologies and bioinformatics processes. Collaborative
research involving local and international teams will help maximize the impact of analytical outputs on the opera‑
tional needs of NMCPs. Research is also needed to explore the cost-effectiveness of genetic epidemiology for differ‑
ent use cases to help to leverage funding for wide-scale implementation. Engagement between NMCPs and local
researchers will be critical throughout this process.
Keywords: Plasmodium falciparum, Plasmodium vivax, Malaria, Surveillance, Molecular surveillance, Genotyping,
Genomics, SNP barcode
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Background
Malaria remains a major public health burden in the
Asia–Pacific region, with an estimated 10 million cases
and 15 thousand deaths in 2018 [1]. Nonetheless, there
has been a substantial decline in malaria cases over the
last 2 decades, that has enabled national malaria control
programmes to start implementing strategies for malaria
elimination. In 2009, the Asia Pacific Malaria Elimination
Network (APMEN) was established to address the unique
challenges of malaria elimination in the region, through
knowledge exchange, capacity strengthening and building the evidence base for elimination [2, 3]. Several years
later, the Asia Pacific Leaders Malaria Alliance (APLMA)
was formed to enhance and streamline regional response
to malaria, with the goal of eliminating this disease from
the region by 2030. However, the challenges to achieve
this goal are considerable.
The revolution in genomic technologies has created new opportunities to study how malaria parasites
adapt and spread within and across borders and has the
potential to help answer key epidemiological questions
that could help NMCPs form better elimination strategies. However, there are currently significant obstacles
preventing wide adoption of molecular technologies to
endemic countries and their integration into national
public health systems. Recent reviews have discussed
the challenges of integrating genomic surveillance for
malaria in Africa [4–6]; similarly, the authors sought to
dissect the challenges hindering the adoption of genomic
technology in the Asia–Pacific region. Although the burden of malaria in the Asia–Pacific region is considerably
lower than that in Africa, the region faces additional challenges of a high proportion of non-falciparum malaria, as
well as being the epicentre of the emergence of resistance
against frontline anti-malarials, such as artemisinin and
its partner drugs [7–10].
In November 2019, the Menzies School of Health
Research (Menzies), in collaboration with the Eijkman
Institute for Molecular Biology (Eijkman), conducted a
two-day parasite genotyping workshop in Jakarta, Indonesia. The concept for the workshop stemmed from discussions within APMEN around the need to address the
challenges of parasite genetic surveillance in the region.
As a result, APMEN participants from 21 countries, as
well as several self-funded collaborators were invited
to join the 2 day workshop, which was co-funded by
APMEN, the Australian Department of Foreign Affairs
and Trade (DFAT) and the Australian Center of Research
Excellence in Malaria Elimination (ACREME). The meeting was attended by 70 participants, with representatives
from 8 malaria-endemic countries in the Asia–Pacific
region; Bhutan, Bangladesh, Pakistan, Thailand, Vietnam,
China, Indonesia and Papua New Guinea. Participants
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included representatives of NMCPs, researchers, United
Nations Children’s Fund (UNICEF) and the World Health
Organization (WHO). The aim of the workshop was to
review recent advances in molecular approaches for Plasmodium falciparum and Plasmodium vivax parasite surveillance and explore ways in which novel surveillance
strategies could be integrated into policy and practice.
This reports key messages, with specific focus on the
following topics:
I. Use cases for parasite genotyping in surveillance.
II. Technical challenges in implementing genotyping
in-country.
III. Data sharing within and between countries.
IV. Maximizing the value of parasite genotyping for
NMCPs.
Use cases for parasite genotyping in surveillance

Dr Sarah Auburn, from Menzies, gave an overview of use
cases for genetic epidemiology that support the operational needs of NMCPs [11], and led discussions centred
around assessing their local utility, as well as identifying
new relevant use cases.
Detect resistance

Following the widespread failure of chloroquine and
sulfadoxine-pyrimethamine (SP) treatments against P.
falciparum, the implementation of artemisinin-based
combination therapy (ACT) in the early-to-mid 2000s
has been a major contributor to the remarkable success in
case reductions in the Asia–Pacific region [1]. Therefore,
the emergence and spread of P. falciparum strains resistant to artemisinin and some of its ACT partner drugs in
the Greater Mekong subregion (GMS) is a major concern
that has elicited an emergency response to contain further spread. Clinical, laboratory and molecular studies
have identified that mutations in the k13 gene located on
chromosome 13 of P. falciparum determine and modulate resistance to artemisinin [12–14]. Although multiple k13 mutations have been associated with artemisinin
resistance, the C580Y mutation has become dominant
in the GMS in the last few years [15]. Mutations associated with resistance to ACT partner drugs have become
widespread, including copy number amplifications of
the plasmepsin 2/3 genes (pfpm2/pfpm3) and the multidrug resistance 1 gene (pfmdr1), which confer resistance
to piperaquine and mefloquine respectively [16–18].
Genetic correlates of parasite resistance to several commonly used anti-malarials in the Asia–Pacific region are
summarized in Table 1. The malaria Genomic Epidemiology Network (malariaGEN) community has developed
a set of rules for classifying parasites in terms of drug
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Table 1 Summary of genetic correlates of drug resistance in P. falciparum and P. vivax
Species

Anti-malarial

Country (policy)a

P. falciparum Artemisinin derivatives BD, BT, KH, CN, ID, IN, LA,
MY, MM, NP, PH, PG, SB,
TH, TL, VU, VN

P. vivax

Gene

Validated mutations

Associated mutations

References

pfkelch13

Y493H, R539T, I543T,
R561H, C580Y

P441L, F446I, G449A,
N458Y, M476I, N537D,
P553L, V568G, P574L,
M579I, D584V, A675V,
H719N

[12, 13]

Piperaquine

CN, ID, MM, TH, VN

Mefloquine

KH, MY, MM

pfmdr1

pfpm2/pfpm3 ≥ 2 copies of the gene

Lumefantrine

BD, BT, CN, ID, LA, MM, NP,
PH, PG, SB., TL, VU

pfmdr1

–

Chloroquine

ID, KR, SB (IPT), VU (IPT)

pfcrt

K76T with; M74I and N75E, –
or C72S

[87]

pfmdr1

–

N86Y, S1034C, N1042D,
D1246Y

[84, 88]

≥ 2 copies of the gene

–

[16, 17]

S1034C, N1042D

[18, 83, 84]

N86Y,

[85, 86]

Sulfadoxine

ID, PG (IPT)

pfdhps

S436A, K437G, K540E,
A581G, A613S/T

–

[89, 90]

Pyrimethamine

PG (IPT)

pfdhfr

C50R, N51I, C59R, S108N,
I164L

–

[89]

Amodiaquine

CN

pfcrt

C72S and K76T

–

[91]

pfmdr1

–

N86Y, D1246Y

[81, 91]

Pyronaridine

CN

–

–

–

–

Primaquine

ID, IN, LA, NP, PH

–

–

–

–

Quinine

BD, BT, KH, ID, IN, MY, MM,
PH, KR, SB, TL, VN

–

–

–

–

Chloroquine

BD, BT, CN, KP, ID, MM, NP,
PH, KR, SL, TH, VN

pvcrt-o

–

Increased expression,
14 TGAAGH motifs in
intron 9

[25, 26]

Intergenic

–

15 TGAAGH motifs at
MS334 (upstream of
pvcrt-o)

[26]

pvmdr1

–

Increased expression,
Y976F, F1076L

[25, 92, 93]

Sulfadoxine

–

pvdhps

–

A383G, A553G

[94, 95]

Pyrimethamine

–

pvdhfr

–

F57L, S58R, T61M, S117T,
S117N

[96–101]

Mefloquine

KH, MY

pvmdr1

–

Amodiaquine

–

pvmdr1

–

Y976F

[96]

–

–

–

–

Artemisinin derivatives KH, IN, LA, MY, PH, PNG,
SB, TL, VU

≥ 2 copies of the gene

[102–104]

Piperaquine

CN, IN

–

–

–

–

Lumefantrine

LA, MY, PH, PG, SB, TL, VU

–

–

–

–

Primaquine

BD, BT, KH, CN, KP, ID, IN,
LA, MY, MM, NP, PH, PG,
KR, SB, TH, TL, VU, VN

–

–

–

–

Countries are listed using two letter codes BD Bangladesh, BT Bhutan, KH Cambodia, CN China, IN India, ID Indonesia, KP DPR of Korea, KR Rep. of Korea, LA Lao PDR,
MY Malaysia, MM Myanmar, NP Nepal, PH Philippines, PG PNG, SB Solomon Is., TH Thailand, TL Timor-Leste, VN Vietnam, VU Vanuatu
a

Countries in the Asia–Pacific region where the given anti-malarial drug is implemented as national drug policy (alone or in combination) for treatment of
uncomplicated unconfirmed, uncomplicated confirmed or severe P. falciparum or P. vivax infection, or for intermittent preventative treatment in pregnant women
(IPT) [1]

resistance, based on the alleles detected at these markers
[19].
Surveillance of P. falciparum drug resistance was
raised as one of the highest priorities of participants
from high and intermediate transmission regions in the

GMS and other areas. Until recently, there was no convincing evidence of artemisinin resistance in the Pacific
region. Olivo Miotto from the Mahidol Oxford Research
Unit (MORU), Thailand, described the recent detection
of three P. falciparum infections in Wewak, Papua New
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Guinea (PNG) [118], which carried C580Y mutations on
a genetic background distinct from that observed in the
GMS, highlighting the importance of vigilance across the
region. Alyssa Barry from Deakin University, Australia,
presented data on behalf of STRIVE (Stronger Surveillance and Systems Support for Rapid Identification and
Containment of Resurgent or Resistant Vector Borne
Pathogens) PNG, an international team including the
PNG NMCP and PNG Institute of Medical Research,
showing that these mutations had not yet spread to other
parts of the country, and no clinical resistance has been
detected.
Molecular surveillance of determinants of anti-malarial drug resistance was acknowledged as an important
early warning system to identify hotspots of resistance,
prioritizing where therapeutic efficacy surveys should
be conducted, and informing on which alternative treatment regimens could be effective in areas with high levels of failures against the current frontline treatment.
Nguyen Thuy-Nhien from the Oxford University Clinical
Research Unit (OUCRU), Vietnam, described large-scale
molecular surveillance at 50 sites in 9 provinces of Vietnam, implemented as part of the GenRe-Mekong project
in close collaboration with the NMCP. This implementation leverages on SpotMalaria (https://www.malariagen
.net/projects/spotmalaria), a technology framework
providing high-throughput genotyping of malaria parasites at a broad selection of single nucleotide polymorphisms (SNPs). SpotMalaria genotypes all k13 mutations,
pfpm2/pfpm3 amplifications, and most important markers of resistance to current and historical drugs, as well
as a genetic barcode of 101 neutral SNPs and variants
informative of co-infecting species. Since the project’s
establishment in 2017, information provided by GenReMekong, in collation with clinical data, has contributed
to anti-malarial drug policy changes in two provinces in
Vietnam, underscoring the great translational utility of
this genotyping use case.
In many Asia–Pacific countries, chloroquine is still
the recommended first-line treatment for blood stage P.
vivax. In Cambodia, Indonesia, Malaysia, PNG, Vanuatu
and Solomon Islands, high rates of chloroquine failure
against P. vivax have led to a policy change towards ACT
as first-line treatment for all species of malaria [20–22].
Jutta Marfurt, from Menzies, gave an overview of antimalarial drug resistance in P. vivax, emphasizing the lack
of validated molecular markers of clinical chloroquine or
artemisinin resistance in this parasite (Table 1).
Although the Y976F mutation in the P. vivax multidrug resistance 1 gene (pvmdr1) is frequently genotyped
in research studies, this variant is a minor modulator
of chloroquine sensitivity and, therefore, not informative in the absence of phenotypic data from clinical or
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laboratory studies [23]. The role of the P. vivax chloroquine resistance transporter gene (pvcrt-o) also remains
unclear, with conflicting patterns of association between
pvcrt-o expression and chloroquine susceptibility
observed in field studies [24, 25]. A repeat-length polymorphism associated to changes in pvcrt-o expression
has recently been identified in a laboratory-based study,
but further evaluation is needed in patients with clinical disease before it is used as a marker of chloroquine
resistance [26]. The absence of molecular markers for
P. vivax remains a major gap in molecular surveillance
frameworks.
Assess drug resistance gene flow

Identifying reservoirs of drug resistant strains, and the
routes through which they spread, within and across borders, can help NMCPs to map the geographical areas at
greatest risk of treatment failures, and plan suitable interventions and alternative treatment strategies. Genetic
data on malaria parasites can provide deep insights on
the origins and genetic make-up of drug resistant variants, and the lineages that carry them. Combining newly
generated and publicly available whole genome sequencing data, Miotto and colleagues were able to demonstrate
that the three PNG C580Y mutants in Wewak were not
imported from the GMS; rather, they shared close genetic
relatedness to Papua Indonesian isolates and carried a
C580Y mutation that has arisen independently [118].
An alternative approach to whole genome sequencing is
genotyping highly polymorphic markers in the regions
flanking the drug resistance variant(s); for example,
Imwong and colleagues used flanking microsatellites to
reconstruct the routes of spread of a C580Y mutant lineage in the GMS [27]. However, aligning microsatellitebased datasets generated by different groups can be
difficult, and artefacts such as stutter can be problematic
for reliable genotype calling [28]. An informative SNP
panel needs to be developed to enable a high-throughput
approach for monitoring gene flow.
Assess transmission intensity

Determining transmission intensity is critical for
NMCPs to monitor progress and optimize intervention strategies in different areas; for instance, to identify where to focus resources for interrupting residual
transmission and minimizing the risk of imported
parasites in areas close to malaria elimination. Traditional surveillance methods incorporating tools such
as microscopy and rapid diagnostic tests (RDTs) can
gauge the prevalence or incidence of infections but rely
on local treatment-seeking behaviour and diagnostic
accuracy. Amplification of parasite DNA, such as Polymerase Chain Reaction (PCR), improves diagnostic
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sensitivity but is still reliant on effective methods for
detecting infected individuals. Parasite genotyping has
been proposed as a complementary method to provide information on the parasite population dynamics
in a given area, by estimating indices of transmission
intensity from genetic data. In some endemic settings,
the frequency of polyclonal infections or complexity of infection (COI) are good correlates of transmission intensity [29], since polyclonal infections are more
commonly observed in high transmission areas, where
more infected mosquitoes provide greater opportunity
for superinfection. However, such relationships are not
necessarily observed in all settings, possibly because of
imported infections [30, 31], differences in sampling
methods [32], or differing marker sets or genotype calling methods. Several statistical methods are available
to estimate polyclonality: for instance, Multiplicity of
Infection (MOI) is often applied to microsatellite-based
datasets, within-sample fixation index (FWS) to genomic
SNP datasets, and the likelihood-based COIL method
for measuring COI using SNP barcodes [28, 33, 34].
Several genotyping platforms are available for assessing COI. Traditionally, parasite genotyping has used
PCR to amplify gene regions with repeat-length polymorphisms, such as the P. falciparum merozoite surface
proteins 1 and 2 (pfmsp1 and pfmsp2) and orthologous
P. vivax gene families or microsatellites [35–39]. Multiple clone infections can be detected by the presence of
multiple PCR amplicons of differing lengths as detected
by investigation of band patterns on agarose gels or capillary sequencing. In recent years, deep sequencing of a
targeted selection of highly diverse gene regions using
amplicon sequencing on massively parallel sequencing
platforms such as Illumina, has become the favoured
approach to characterize the complexity of malaria
infections [40]. The extensive depth of sequence reads
generated by amplicon deep sequencing (100–1000 s
of reads per target gene depending on the sequencing
conditions) enables substantially greater sensitivity to
detect minor clones than capillary sequencing. Studies in PNG, where transmission is high and infections
are frequently complex, have demonstrated the detection of minor P. falciparum clones at a detection limit
of 1:1000, and used these methods to track longitudinal infection dynamics with high sensitivity [41–43].
Amplicon deep sequencing has also been used in P.
vivax to compare infection dynamics between day 0
and recurrent infections [44]. Several analysis tools
have been developed to support the analysis of infection complexity using deep sequencing data, including
PASEC, DADA2, HaplotypR and SeekDeep [43, 45–
47]. Despite differences in their approach, these four
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state-of-the-art tools resolved known haplotype mixtures with similar sensitivity and precision [47].
The study of genetic relatedness and population structure can also be informative of transmission levels: studies of both P. falciparum and P. vivax have observed
increasing genetic relatedness between infections as
parasite populations dwindle, as inbreeding and clonal
transmission becomes predominant [48–53]. Shrinking
populations tend to form moderately distinct pockets (or
foci) of infection, which translate to changes in population structure, often modulated by external factors. In
contrast to conventional methods such as microscopy or
RDTs, genetic indices require representative sampling,
but are not reliant on comprehensive sampling, which
makes them potentially robust tools for assessing transmission intensity.
An example of the use of endemicity data by NMCPs
was provided by Nancy Dian Angraenni from the Ministry of Health, Indonesia. She outlined the “island by
island” malaria elimination strategy in Indonesia, where
areas are categorized according to the local endemicity, and control activities are applied in stages from the
regency/city administrative levels to the provincial and
then regional and national levels. These efforts require
detailed maps of malaria risk to guide the strategic distribution of limited resources, with regular updates as
control progresses [54]. A better understanding of how
genetic indices correlate with malaria elimination categories will help to stratify interventions in areas where
regular and comprehensive surveillance by conventional
methods is not feasible.
Identify foci of infection

This use case defines target areas for tailored interventions; examples include localizing hotspots of transmission in heterogenous regions, or residual transmission
foci in low endemic areas. This is not a high priority in
high transmission areas, where infections tend to be uniformly distributed and distinct foci of infection are generally rare [55]. However, as transmission declines and
parasite populations shrink, distinct foci of infection
begin to emerge. These are currently identified from geospatial surveillance and case investigations, but detection
can be improved by comparing the parasite genetic relatedness within versus between foci [11]. Further research
is needed to determine operationally relevant spatial
scales for defining the boundaries of foci, and the stability
of these foci over time.
Determine connectedness between parasite populations

Estimating the connectedness between parasite populations can help gauge the risks of parasites spreading between geographic areas. This information is
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particularly important for locating major reservoirs
(“sources”) that are sustaining infections in other areas
(“sinks”). Connectedness can be estimated using human
mobility data, such as patient travel history or mobile
phone data, but two recent studies highlight the potential of combining these data with parasite genetic data, to
reveal both local and long-distance parasite transmission
routes [56, 57]. In contrast to mobile phone data, which
provide information about movement of the human population, genetic data offer a view on parasite gene flow,
whose routes may differ from those followed by people.
Furthermore, genetic data is not restricted to the coverage of mobile networks, which is particularly valuable
across country borders [56, 57].
A classical approach used to quantify connectedness
between populations is the assessment of genetic differentiation using the fixation index (FST) [58]. This measure has been used widely in microsatellite-based studies
of P. falciparum and P. vivax, providing useful insights on
the connectedness between populations at a moderately
granular scale [59]. However, FST does not account for
recombination, and is constrained in its ability to infer
fine-resolution connectedness [60]. Conversely, measures
of identity by descent (IBD) apply a probabilistic model
accounting for recombination and can provide insights
into more recent demographic changes. IBD is increasingly being used to assess parasite connectedness at
relatively small spatial scales [60–62]. Tools for measuring IBD include isoRELATE, hmmIBD and DEploid-IBD
[61–63].
Low-resolution genetic studies of co-endemic P. falciparum and P. vivax in Indonesia and PNG have demonstrated higher connectedness amongst P. vivax
populations, highlighting the greater potential for this
species to spread via the hypnozoite reservoir [64, 65].
Rintis Noviyanti, from Eijkman, described plans to
expand on the maps of parasite connectedness across
Indonesia using high-throughput SNP-based genotyping
methods. Alyssa Barry and Livingstone Tavul, from the
PNG Institute for Medical Research, described similar
plans for PNG. The evidence generated from these studies will be shared with the local NMCPs, with a view to
implementing them more widely within local surveillance frameworks.
Identify imported cases and transmission chains

In low-endemic areas of the Asia–Pacific region, border malaria and imported cases pose major challenges
to malaria elimination, particularly in areas with highly
mobile human populations. Figure 1 illustrates the relative proportions of autochthonous versus imported
infections in different countries in the region. The meeting agreed on the importance of distinguishing between
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border and imported malaria, since these reflect distinct challenges with different surveillance and response
needs. Duoquan Wang from the National Institute of
Parasitic Diseases at the Chinese Centre for Disease
Control, and Yaobao Liu from the Jiangsu Institute for
Parasitic Diseases, China, described China’s remarkable
success in reducing indigenous malaria cases from 24
million in 1970 to zero since 2017 [1], and highlighted
post-elimination surveillance of border and imported
malaria as one of the highest priorities for maintaining a
malaria-free status. Liu described the malaria situation in
Jiangsu province of central China [66], and the broader
situation in China, describing how most reported infections in the past few years were suspected importations
from Africa (~ 80% P. falciparum) and southeast Asia
(~ 80% P. vivax) [67]. In several high transmission countries, there is interest in tools for surveying imported
cases of P. falciparum from regions such as the GMS
where artemisinin-resistance is prevalent.
At present, imported cases are usually identified and
mapped using information on patient travel history.
However, the procedure followed has been designed
specifically for P. falciparum malaria, without consideration for the delayed relapses of P. vivax, which may lead
to incorrect conclusions. Molecular tools to identify
and map imported malaria cases offer a complementary approach to traditional epidemiology. Table 2 summarizes different molecular approaches that have been
used to map imported P. falciparum and P. vivax cases.
Hidayat Trimarsanto described a collaborative project
between Eijkman and global partners within the vivax
Genomic Epidemiology Network (vivaxGEN), to develop
molecular tools for identifying and mapping imported
P. vivax cases. Investigation of genomic data from 831
P. vivax genomes from 20 countries identified 28 new
genetic markers that can be used to distinguish imported
from local infections [68]. A web-based tool, vivaxGENGEO, was developed to map country of origin, even in
the presence of missing or heterozygous genotype calls
(https://geo.vivaxgen.org/).
Duoquan Wang described the challenge of border
malaria in Yunnan Province, southern China, which
shares hundreds of kilometres of border with Myanmar [69]. Cross-border parasite flow is high along large
stretches of the border region, with most cases believed
to migrate from Myanmar into China; analogous crossborder flow in Bhutan’s southern districts neighbouring India were reported by Kesang Wangchuk from the
Ministry of Health, Bhutan. The challenge is more pronounced for P. vivax than P. falciparum, as dormant
hypnozoites can enable longer persistence of P. vivax
infections and accordingly wider dispersal. High rates
of parasite flow across porous border regions result in
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Fig. 1 Imported case proportions and total malaria case numbers in the Asia–Pacific region in 2018. a presents the percentage of imported
cases (all species of malaria) in 2018 in order of highest to lowest percentage. b presents the total number of presumed and confirmed cases (for
all species) in 2018 in the same order as (a). The numbers were derived from the World Malaria Report 2019 summary of reported malaria cases
by method of confirmation 2010–2018 for countries in the WHO Southeast Asia and Western Pacific region. The percentage of imported cases
was calculated as the number of imported cases divided by the total number of presumed and confirmed cases. The countries with the highest
proportion of imported cases have amongst the lowest number of overall cases

relatively homogenous parasite populations in neighbouring countries, hampering classification of local from
imported cases using categorical classification-based
methods such as vivaxGEN-GEO. Whilst country classifications may be difficult to obtain using genetic data
in highly porous border regions, genotyping can potentially be useful to decipher parasite transmission chains;
using genetic barcodes to distinguish infections, the
transmission of individual parasite strains can be traced
from one individual to another. This information can be
used to monitor whether cases with travel history from
across the border have been transmitted locally. It was
agreed by the meeting that genetic homogeneity between
neighbouring parasite populations poses significant challenges to monitoring malaria importation and provides
a strong case for cross-country collaborative efforts and
data sharing.
Detect HRP2/3‑based rapid diagnostic test failures

Plasmodium falciparum infections with deletions of
histidine-rich protein 2 and 3 (HRP2 and HRP3) may go
undetected by several RDTs [70]. Recent insights from

genomic data on P. falciparum indicate that up to 25% of
infections in Papua Indonesia and PNG have HRP3 deletions [19], suggesting that molecular surveillance of these
parasites is needed. However, molecular analysis of HRP2
and HRP3 variants affecting RDT efficacy remains complex. The WHO recommends PCR-based methods to
analyse the exons and flanking genes of HRP2 and HRP3,
and a 7-point quality scoring system based on recommendations by Cheng and colleagues [71]. To date, there
are no high-throughput frameworks for surveillance of
these genes.
Characterize outbreaks

Countries with a high burden of malaria have a huge
challenge in providing robust surveillance systems and
thus are often not able to assess geospatial and temporal trends such as outbreaks, undermining optimal
responses to malaria control [1]. Several molecular methods are available to investigate outbreaks, using methods
similar to those used for detecting transmission chains.
Using genetic barcodes to compare infections, it is possible to identify the rapid clonal expansion of specific

a

Primers available to amplify the gene
regions

Primers available to amplify the gene
regions of a 9-marker set used by the
APMEN vivax Working Group

Primers available to amplify the gene
regions

Assays

[108, 109]

[105–107]

Publications

Mitochondrial and apicoplast genomes
are historically conserved and robust to
recombination. Addition of the apico‑
plast genome provides more variants,
increasing resolution. Robust regionallevel resolution

[114]

Mitochondrial genome is historically con‑ [110–113]
served and robust to recombination.
Extensive reference datasets available
from across the globe in GenBank.
Lower resolution than genome-wide
SNP barcodes

Microsatellites are often neutral but
have high mutation rates constraining
geographic ancestry. A single marker
(MS20) appears to discriminate temper‑
ate from tropical P. vivax infections.
Lower resolution than genome-wide
SNP barcodes

Diversity may reflect selection from the
host immune system, rather than geo‑
graphic ancestry. Lower resolution than
genome-wide SNP barcodes

Comments

Targeted SNP genotyping In silico at present but Illumina amplicon
sequencing and minION assays in
development

Less robust to effects of recombination
[68]
over time than mitochondria and api‑
coplast. Robust country-level resolution
in many areas. Online data analysis tool
available, amenable to missing data and
polyclonal infections: vivaxGEN-GEO
(https://geo.vivaxgen.org/)

Targeted SNP genotyping Real-time PCR high-resolution melt (HRM) Less robust to effects of recombination
[115]
assays. Amplicon sequencing Illumina
over time than mitochondria and apico‑
assays
plast. Robust regional-level resolution

Targeted SNP genotyping In silico only (no assays developed to
date)

Capillary sequencing

See Table 3 for comparative assessments of different genotyping approaches

28-SNP, 50-SNP and 51-SNP genome-wide P. vivax
barcodes

P. vivax

42-SNP genome-wide barcode

P. falciparum and P. vivax Capillary sequencing

Mitochondrial genes

P. falciparum

P. vivax

Microsatellites

23-SNP mitochondrial and apicoplast
barcode

P. vivax

Variable surface antigens: pvcsp and
pvmsp1

Capillary sequencing

Species

Markers

Platforma

Table 2 Molecular methods to identify and map the geographic origin of malaria infections
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strains, possibly indicating that they possess some fitness
advantage [49]. Concurrent genotyping at relevant drug
resistance determinants, geographic markers to identify
imported cases and HRP deletions can add additional
information to support such investigations.
Characterize recurrent P. vivax infections

The characterization of recurrent P. vivax infections was
also deemed to be a genetic use case in the Asia–Pacific
region. Relapses deriving from dormant liver-stages
(hypnozoites) are the main contributor to the transmission of P. vivax infections, as they may be the source of
over 80% of all cases [72, 73]. Distinguishing relapses
from reinfections is complex, since hypnozoites causing
a relapse may be genetically different from the parasites
that caused the initial infection [74]. Recent studies using
whole genome sequencing data have demonstrated the
utility of molecular data to identify recurrent infections
that are genetically different from day-zero parasites, but
appear to be related, sharing identity by descent [75, 76].
Pairs of day-zero and recurrent parasites that are genetically related are more likely to have derived from the
same mosquito bite than from different inoculations (as
in a reinfection) and are, therefore, more likely to represent relapse rather than re-infection events. Paired P.
vivax isolates have been compared using microsatellites
[119]. Methods using microhaplotypes (short stretches
of the genome which contain multiple SNPs and, therefore, can be treated as a single locus with more than two
alleles) are also in development [42]. However, whilst
small sets of microsatellites and microhaplotypes can
capture genetic similarity due to identity by state (IBS),
they may miss pairs of siblings that have high IBD (> 50%)
but low IBS because of recombination. Sasha Siegel, from
the Wellcome Sanger Institute, described a collaborative
project with Menzies to develop a comprehensive panel
of approximately 100 microhaplotypes across the P. vivax
genome, as an alternative to whole genome sequencing to
determine which pairs of infections are related based on
measures of IBD and, therefore, likely to reflect relapse
events. Mathematical models are being developed to analyse this information in surveillance frameworks, to infer
the underlying burden of relapses from passively collected pairs of infections. The aim of this approach is to
inform on the efficacy of and adherence to primaquine or
other radical cure policies.
Technical challenges in implementing genotyping
in‑country

Discussions around genotyping use cases highlighted a
variety of different needs and priorities for parasite surveillance, largely reflecting the varying endemicity across
the Asia–Pacific region. This raised questions about
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the suitability of a “one size fits all” approach in countries ranging from high burden areas to only handfuls of
imported cases (Fig. 1). Each country needs to choose an
implementation of genetic surveillance that suits their
needs and maximizes the value they can get from the
resources they have available. Indeed, the access to specialized molecular technologies varies widely between
countries: whilst China is world-renowned for its capabilities, with large sequencing centres providing services
to clients across the globe, many other countries in the
region have poor access to genomic services.
The varying access to genomic services fuelled discussion around the pros and cons of whole genome sequencing for parasite surveillance. In the pros, whole genome
sequencing provides the highest genetic information
content on a sample, with the potential to genotype thousands of SNPs, as well as copy number variants (CNVs)
and other structural rearrangements.
Genomic data also provides the greatest potential to
characterize and disentangle polyclonal infections using
methods such as DEploid [63]. With the costs of sequencing continually falling, whole genome sequencing of
malaria parasites is becoming increasingly cost-effective.
However, the cons of whole genome sequencing include
difficulty in obtaining high-quality samples from patient
infections, particularly for low-density P. vivax infections. Although selective whole genome amplification
(sWGA) methods have been established for P. falciparum
and P. vivax to overcome the challenges of low-density
infections and high human DNA contamination [77, 78],
these methods constrain detection of CNVs, and coverage of the P. vivax genome can remain sparse in lowquality samples. The biggest constraints to whole genome
sequencing in many parts of the Asia–Pacific are the limited technical and bioinformatic skills required to achieve
high-quality genomic data and to handle and analyse the
large datasets.
For many of the use cases described, whole genome
data is unnecessary; carefully selected subsets of SNPs
(SNP barcodes) or other variants can provide the information needed by NMCPs. A range of platforms are
available for genotyping SNP barcodes, producing data
that is informative but requires smaller investments
than whole genome sequencing and is more suitable for
entry-level expertise. An example of such an approach
is amplicon sequencing, which performs high-throughput sequencing, but only at loci of interest. As a result,
it is more cost effective than whole genome sequencing,
simpler to analyse, and can still provide a comprehensive profiling of the parasites, by typing drug-resistance
mutations as well as genetic barcodes that “summarize”
the genome. A technical session was held to discuss the
relative pros and cons of amplicon sequencing and other
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genotyping platforms that are currently being considered
for parasite surveillance (see Table 3 for a summary).
Olivo Miotto gave an overview of the SpotMalaria
amplicon sequencing framework and SNP barcodes used
by the GenRe-Mekong project to genotype P. falciparum and P. vivax samples (https://www.malariagen.net/
projects/spotmalaria). An overview of the SpotMalaria
barcodes and several other Plasmodium SNP barcodes
is provided in Table 4. Amplicon sequencing uses highthroughput Illumina sequencers to sequence selected
loci across the Plasmodium genome, enabling multiplexing that allows hundreds of samples to be genotyped in
a single experiment, providing cost-effective genotyping
of large sample sets with high accuracy and sensitivity.
The sensitivity will depend in part on the multiplexing
level and other sequencing conditions, but is potentially
even amenable to leftover clinical material from RDTs
[79]. The platform is flexible to iterative enhancements
and extensions of the SNP barcodes. The reliance on
specialized equipment and reagents, and the need for
highly skilled technicians, limit amplicon sequencing implementations to few laboratories, best achieved
through a centralized genotyping framework within a
given malaria-endemic country, or regional reference
laboratories supporting multiple countries. Networks
such as APMEN, ACREME, vivaxGEN and MalariaGEN
can support regional efforts, promoting standardization
and knowledge sharing. The high-throughput nature of
amplicon sequencing lowers the turnaround time for data
to be returned, which is typically of the order of weeks or
months in current implementations. Although this turnaround is not suitable for supporting point-of-care decisions, it is valuable for use by NMCPs needing to make
policy decisions based on population-level data. The two
examples of policy changes in Vietnam were supported
by population-level genetic data on drug resistance variants (in collation with clinical data), which is provided to
the NMCPs (Institute of Malaria, Parasitology and Entomology in Vietnam) on a quarterly basis (approximately
every 3 months).
Building in-country processing capacity is a primary
objective of the SpotMalaria and GenRe-Mekong genetic
surveillance projects. Implementing high-throughput
pipelines for genetic surveillance promotes ownership of
the process, extends capacity in countries, and potentially
delivers more timely products. To facilitate in-country
implementations, the genotyping framework has been
engineered using an amplicon sequencing approach, so
that it can operate on lower-end Illumina sequencers
and be deployed in malaria-endemic countries. Technology transfer is currently at an advanced stage in Ghana,
the Gambia, Indonesia and Vietnam. Miotto, Nguyen
Thuy-Nhien and Noviyanti described their respective
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experiences of the pros and cons of amplicon sequencing
in malaria-endemic countries. In most cases, the adoption process has been gradual, owing to challenges such
as infrastructure stability (such as electrical power), procuring specialized reagents, and the higher local costs of
equipment, reagents and maintenance. Several endemic
countries are not ready to make such a transition, so it
is essential that they be guaranteed equal access to technology. For this reason, SpotMalaria and GenRe-Mekong
have continued offering processing capacity at the Wellcome Sanger Institute, while encouraging labs in endemic
countries to provide regional processing support for
neighbouring countries.
Alyssa Barry gave an overview of Oxford Nanopore’s
minION platform, which supports rapid data delivery,
potentially within as little as 24 h of sample processing.
The minION is a highly portable sequencer, which can
be deployed in low-resource settings, with a lower startup investment than Illumina sequencers but also lower
throughput, which makes it more suitable for processing
small sets of samples. It is also technically simpler than
Illumina, requiring less specialized skills. This platform
can be used for targeted genotyping of SNP barcodes, as
well as sequencing of large and highly repetitive genomic
regions. The flexibility to sequence entire regions in a
non-targeted manner has potential for detecting new
mutations, but it may be difficult for health workers or
NMCPs to derive useful interpretations on these mutations. The main technical disadvantage of the minION
is its sequencing error rate, higher than that of Illumina.
The high error rate needs correcting by producing multiple reads covering the locus of interest and applying
appropriate statistical methods.
In addition to the laboratory aspects of these genotyping platforms, there were active discussions around
the processing and interpretation of the data they produce. The partners agreed that both the Illumina and
minION platforms present considerable bioinformatics challenges, highlighting the need for local capacity
building to support data handling and analysis. Some
participants identified data processing as a suitable task
for service provision and placed greater importance on
data interpretation and the need for user-friendly data
outputs that can be readily used by control programme
workers who may have limited knowledge of genetics.
Data analysis tools are being developed and are building capacity to address the knowledge gaps between
researchers and control programmes. However, these
tools are in their infancy and further optimization and
development is needed. The SpotMalaria team have
developed an informatics pipeline to support the analysis
of amplicon sequencing data uploaded from the Illumina
sequencer, producing Genetic Report Cards, detailing

One gene region at
a time

One to ~ four mark‑
ers at a time

One marker at a
time

Capillary sequenc‑
ing

Microsatellite typ‑
ing by capillary
sequencing

SNP genotyping by
HRM3

One to ~ 40 markers Moderate to high
at a time

Dozens to hundreds Moderate to high
of markers in
parallel

Amplicon sequenc‑
ing with Illumina,
and Molecular
Inversion Probes

Low to high

Low to high

Low to high

Low to high

Sample
throughput

MassARRAY geno‑
typing

Real-time PCR analy‑ One gene region at
sis of CNVs4
a time

Marker
throughput

Method

High at major and
minor allele5

Moderate at major,
low at minor1

Moderate at major
allele, low at
minor1

Moderate at major
allele, low at
minor1

Moderate at major
allele, low at
minor1

Moderate at major
allele, low at
minor1

Sensitivity

Cost-effective for
moderate-large
sample size and
multiple genes

Cost-effective for
large sample
size and multiple
genes

Weeks

Weeks6

Data handling

Time-consuming to
review multiple
sequence traces

Optimal for CNVs.
Need controls for
every marker on
each run

Not highly acces‑
Digital allele calling. Need specialized skills
sible. Requires
Potential to detect
specialized techni‑
CNVs4. Not feasi‑
cal expertise
ble for detecting
(reference lab
new variants
advised)

Need specialized skills

Time-consuming to
review multiple
sequence traces

Accuracy in geno‑
Time-consuming to
typing heterozy‑
review multiple
gote positions is
sequence traces
constrained. Need
controls for every
marker on each
run

Multi-allelic nature
helps to charac‑
terize polyclonal
infections.
Stutter and other
artefacts can be
problematic

Time-consuming to
Accessibility to
review multiple
moderately com‑
sequence traces
plex sequence
regions. Ability
to detect new
variants and
VNTRs2. Suitable
for genotyping trior quadri-allelic
positions

Sequencing
features

Not highly acces‑
Accuracy in geno‑
sible. Requires
typing heterozy‑
specialized techni‑
gote positions is
cal expertise
constrained
(reference lab
advised)

Not cost-effective
Accessible and
for multiple genes
user-friendly
in a large sample
technology

Not cost-effective
Accessible and
for multiple genes
user-friendly
in a large sample
technology

Not cost-effective
Widely accessible.
for multiple genes
Technical exper‑
in a large sample
tise often avail‑
able in endemic
countries

Not cost-effective
Widely accessible.
for multiple genes
Technical exper‑
in a large sample
tise often avail‑
able in endemic
countries

Accessibility

Days

Days

Days

Days

Test-to-result time Cost
considerations

Table 3 Overview of several genotyping methods used for malaria samples
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Marker
throughput

Sample
throughput
Moderate at major,
low at minor1

Sensitivity
Days

Cost-effective for
small-moderate
sample size and
multiple genes

Test-to-result time Cost
considerations
Highly portable,
accessible and
user-friendly to
run

Accessibility

Ability to detect
new variants
and VNTRs1.
Accessibility to
moderately com‑
plex sequence
regions. High rate
of sequencing
errors

Sequencing
features

Need specialized
skills, but amenable
to more userfriendly platforms

Data handling

Generally not robust to detect minor alleles at intensity lower than 10% of major allele. 2Variable Number Tandem Repeats. 3High Resolution Melt-curve analysis using quantitative PCR. 4Copy Number Variants.
Depends in part on read depth, which is partly determined by the multiplexing level. 6Depends on sample throughput; turnaround time of weeks assumes a moderately large sample throughput for cost-efficacy

5

1

MinION genotyping Dozens to hundreds Low to high
of markers in
parallel

Method

Table 3 (continued)

Noviyanti et al. Malar J
(2020) 19:271
Page 12 of 20

UCSF 100 microhaplotypes

4

P. vivax

P. vivax

WEHI 148 SNPs

2

Menzies-Sanger 100 microhap‑
lotypes

100 globally diverse multi-allelic
amplicons

148 SNPs, all neutral variants

38 of 42 Broad SNPs, plus
species-specific variants, drugresistance markers in pvmdr1,
pvdhfr, pvdhps

5

42 polymorphic, neutral vari‑
ants, including region-specific
variants for geographic assess‑
ment

5

[116]

[117]

[42]

[116]

Infection complexity, genetic
relatedness

Infection complexity, genetic
relatedness

Illumina amplicon sequencing (Under development)

Illumina amplicon sequencing Papua New Guinea, Cambodia

Unpublished

Unpublished

Drug resistance prevalence,
Illumina amplicon sequencing Afghanistan, Bangladesh,
Unpublished
species confirmation, infection
Bhutan, Cambodia, Colom‑
complexity, genetic related‑
bia, Ethiopia, Indonesia, Iran,
ness, geographic region
Mauritania, Malaysia, Myanmar,
Republic of Korea, Sudan,
Thailand, Vietnam

Brazil, French Guiana, Ethiopia,
Sri Lanka (and countries
below)

Illumina amplicon sequencing Mozambique

Infection complexity, genetic
High-resolution melt
relatedness, geographic region

Infection complexity, genetic
relatedness

Illumina amplicon sequencing Papua New Guinea, Cambodia

Ethiopia, Malawi, Nigeria,
Panama, Senegal, Zambia,
Zimbabwe

Unpublished

Unpublished

Publication

https://www.malariagen.net/projects/spotmalaria. 2Walter and Eliza Hall Institute of Medical Research. 3Swiss Tropical and Public Health Institute. 4University of California, San Francisco. 5Barcodes designed with
intentional overlap to support data sharing between partners

P. vivax

SpotMalaria 113 SNPs

1

1

P. vivax

Broad Institute 42 SNPs

P. falciparum 100 globally diverse multi-allelic
amplicons

P. falciparum 5 gene regions: cpmp, cpp, ama1- High sensitivity assessment of
D3, csp, msp7
infection complexity, longitu‑
dinal tracking

Swiss TPH 5 genes

High-resolution melt

3

Infection complexity, genetic
relatedness

P. falciparum 24 polymorphic, neutral variants

Broad Institute 24 SNPs

Papua New Guinea, Solomon
Islands, Mali

P. falciparum 155 SNPs all neutral variants, a
Infection complexity, genetic
Fluidigm SNPType™
subset are geographic markers
relatedness, geographic region Assay

WEHI 155 SNPs

2

Countries implementing
the panel

P. falciparum 101 SNPs including neutral vari‑ Drug resistance prevalence,
Illumina amplicon sequencing Bangladesh, Cambodia, Ghana,
ants, species-specific variants
species confirmation, infection
Benin, Brazil, Cameroon,
and drug-resistance markers
complexity, genetic related‑
Colombia, Congo, Ethiopia,
in K13, pfcrt, pfdhfr, pfdhps,
ness
The Gambia, Guinea, India,
pfmdr1 and pfpm2/pfpm3 SNPs
Indonesia, Kenya, Laos,
and copy number,
Malaysia, Mali, Myanmar, Peru,
Senegal, Sudan, Tanzania,
Thailand, Vietnam

Genotyping platforms

SpotMalaria 101 SNPs

Applications

1

Description

Species

Marker panel

Table 4 Overview of several SNP panels for barcoding P. falciparum and P. vivax infections
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individual-level information on the presence of mutations that confer resistance to a variety anti-malarial
drugs in each infection (https://www.malariagen.net/
projects/spotmalaria). In addition, GenRe-Mekong delivers reports containing maps of population-level drug
resistance prevalence for different drugs, shown using
intuitive “traffic light” colour representations (example
in Fig. 2). Whilst the importance of user-friendly tools
for the NMCPs was widely agreed on, there was also a
keen interest in strengthening the local research capacity. The malaria research outputs from Eijkman provide
inspiring examples of the potential for developing local
bioinformatics expertise in the region. Collaborative
projects between Eijkman and Menzies have established
web-based, open access genetic data analysis tools such
as vivaxGEN-GEO [68], vivaxGEN-MS [80], and vivaxGEN-SNP (in development). The vivaxGEN-MS platform
currently hosts data from 11 countries and has supported
data analysis for 10 publications to date. Enhancing local
research in genetics and genomics will enable countries
to implement molecular surveillance tools and tailored
them to specific local needs.
Data sharing within and between countries

The workshop discussed the relevance of data sharing
to both researchers and NMCPs, along with the challenges that needed to be addressed. The consensus
was that data sharing between institutions and across
national borders is crucial for addressing use cases such
as drug resistance gene flow, connectivity between populations, and border and imported malaria. There were
no anticipated political obstacles to data sharing within
countries. However, some countries perceive intellectual property as a potential challenge in sharing data.
In other countries, such as Indonesia, national export
restrictions constrain sharing of the raw sequence reads
generated by whole genome sequencing. Such restrictions challenge open access but can be mitigated by
sharing “intermediate datasets” such as the genotype
calls used in whole genome sequencing studies, which
ensures that the results are reproducible (e.g. [81] provides genotype calls in a vcf file format). Furthermore,
this ensures that genotyping data produced at microsatellites or SNP-based barcodes can be made open
access. The value of converging on commonly structured datasets was also discussed; for example, whether
the broad range of SNP barcodes available for different
use cases would be a challenge in sharing data between
sites where there is little or no overlap in the SNP panels. The participants acknowledged that markers tailored to a specific country or region may have higher
resolution than global marker sets to resolve the local
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genetic microepidemiology; however, they agreed that
consensus was needed to ensure that at least part of the
data generated in each country could be shared with
others to support regional surveillance. For use cases
such as assessment of transmission intensity, consensus markers would strengthen comparability between
sites, but are not essential. However, for use cases that
aim to assess the connectivity or drug resistance gene
flow between populations, overseas importation, or
cross-border transmission, a consensus marker set
is critical. In addition, platforms and tools to support
data sharing between partners within and across borders can overcome inability to share data due to a lack
of mechanisms to do so effectively. Networks such as
APMEN, ACREME, vivaxGEN, the Worldwide Antimalarial Resistance Network (WWARN) and MalariaGEN
are important forums to support consensus and data
sharing between countries. The APMEN vivax working group has been successful in establishing consensus
for microsatellite-based genotyping markers across the
network, when this technology was still the favoured
genotyping method for P. vivax [80]. The network has
also helped establish a platform supporting openaccess sharing of the microsatellite-based genotyping
data [80]. For SNP-based data, the platform underpinning GenRe-Mekong and SpotMalaria automatically
aggregates data, presenting regional and global views.
Data sharing can be integrated into the processing
pipelines and thus come at no extra effort for the country. Ownership of the data is retained by the country,
and adequate recognition and visibilities are given to
the contributing party when the data are aggregated.
Ethical aspects of genetic surveillance were raised;
specifically, it was highlighted that patient informed
consent and assent can add a large additional work-load
on top of routine tasks. Furthermore, the primary goal
of surveillance outputs is to inform public health rather
than to conduct research. In the Lao People’s Democratic Republic and Thailand, NMCPs are considering
requesting an exemption from collecting additional
patient consent, justified by the integration of sample
collection in the standard treatment procedures, and
the public health benefits of the resulting outputs. A
critical condition for such exemption is that no human
genetic data is collected. Different solutions will have to
be adopted by countries that deem it important to genotype human genetic variants, for example to establish
the prevalence of glucose-6-phosphate dehydrogenase
(G6PD) variants or cytochrome P450 2D6 (CYP2D6)
variants that have implications for the safe and effective
administration of primaquine [82].
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Fig. 2 Example of a GenRe-Mekong drug resistance prevalence “traffic light” plot. Example of a map generated by the SpotMalaria GenRe-Mekong
project, showing the predicted prevalence of artemisinin-resistant parasites at sites in 6 provinces of Vietnam before September 2018. District-level
drug resistance-associated allele frequencies are coloured according to prevalence (ranging from 0–100% in a spectrum from green to red).
Courtesy of the Institute of Malariology, Parasitology and Entomology, Quy Nhon and OUCRU, Vietnam
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Maximizing the value of parasite genotyping for control
programmes

The workshop ended with a session on maximizing the
value proposition of molecular surveillance for malaria
control programmes. Miotto highlighted that “it’s hard
to appreciate the value of something you don’t have, and
hard to predict what you will use in the future”. The full
value and potential of genotyping tools may only be realized once they are actively implemented within surveillance frameworks on a wider scale. In order to reach
that stage, the research community needs to ensure that
they gain a good understanding of NMCPs activities, to
ensure the molecular applications they develop serve
these needs optimally. As emphasized by the Indonesian
NMCPs, regular engagement between local researchers
and NMCPs will be critical to achieve this. Ferdinand
Laihad and Endang Sumiwi, from the Indonesian NMCP,
emphasized the value of bringing together participants
from different countries to share their local knowledge
and experiences in malaria control and elimination.
There was active discussion concerning the financing
of comprehensive surveillance frameworks. To achieve
the routine and widespread sampling and processing
needed for an informative surveillance operation, a stable
source of funding is needed from local governments, the
WHO, or other international funding agencies. Inclusion
of genetic epidemiology in WHO policy will be needed
to leverage funds from the Global Fund. It was widely
agreed that more evidence of policy changes, as observed
in Vietnam, and demonstration of the advantages and
potential cost-saving of genetic surveillance tools are
needed to encourage increases in funding from local governments and other key stakeholders. Large-scale evaluations of the cost-effectiveness of different use cases will
be invaluable.

Conclusion
The elimination of malaria from the Asia–Pacific region
by 2030 presents a spectrum of formidable challenges
and innovative approaches both within and between
countries are needed. Molecular surveillance offers great
potential to generate knowledge that will allow NMCPs
to keep ahead of the constantly changing and evolving
dynamics of parasite populations. Considerable work is
still needed to support the implementation of genomic
technologies and bioinformatics capacity in the region.
Further research is needed to optimize methodologies
for several use cases, and to build the evidence base on
the utility and cost-efficacy of genetic epidemiology, to
help leverage funding and logistic support for wide-scale
genetic and genomic surveillance in-country. Engagement between NMCPs and researchers will be critical
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at each step, to ensure that these efforts meet the operational needs of malaria elimination.
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